This is a working overview of nasal drops, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-08-20. Anything still debated is marked as such rather than presented as settled.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Analogue of the ACTH(4-10) fragment |
| Amino acid sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Single-letter form MEHFPGP |
| Molecular formula | C37H51N9O10S | Free peptide, nominal mass near 814 Da |
| First registration | 1994, Russia | Nasal formulation for neurological indications |
| Typical purity grade | 95% or higher by HPLC | Research material; higher grades used as reference standards |
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
Agragen, in collaboration with University of Alberta – docosahexaenoic acid and human serum albumin in flax Chlorogen, Inc. – cholera, anthrax, and plague vaccines, albumin, interferon for liver diseases including hepatitis C, elastin, 4HB, and insulin-like growth factor in tobacco chloroplasts. Went out of business in 2007. Dow Chemical Company made a deal with Sunol Molecular in 2003 to develop antibodies against tissue factor in plants and in mammalian cell culture and to compare them. In 2005 Sunol sold all its tissue factor antagonists to Tanox, which in turn was bought by Genentech in 2003. Genentech licensed the tissue factor program to Altor in 2008 Altor is itself a spinout from Sunol. The product under development, ALT-836, formerly known as TNX-832 and Sunol-cH36, is not the plant-produced antibody, but rather is a mammalian antibody, more specifically, a chimeric antibody produced in a hybridoma. Epicyte – spermicidal antibodies in corn Epicyte was purchased by Biolex in 2004 at which time Epicyte's portfolio was described as "focused on the discovery and development of human monoclonal antibody products as treatments for a wide range of infectious and inflammatory diseases." Large Scale Biology Corporation (LSBC) (bankrupt) – used Tobacco mosaic virus to develop reagents and patient-specific vaccines for Non-Hodgkin's lymphoma, Papillomavirus vaccine, parvovirus vaccine, alpha galactosidase for Fabry disease, lysosomal acid lipase, aprotinin, interferon Alpha 2a and 2b, G-CSF, and Hepatitis B vaccine antigens in tobacco.
== Horrevoets Trophy == In May 2009, The Ocean Race launched the Hans Horrevoets Rookie Award to recognize the outstanding under-30 sailor in each edition of the race as nominated by the respective skippers. Recipients:
Schymanski, Emma L.; Jeon, Junho; Gulde, Rebekka; Fenner, Kathrin; Ruff, Matthias; Singer, Heinz P.; Hollender, Juliane (18 February 2014). "Identifying Small Molecules via High Resolution Mass Spectrometry: Communicating Confidence". Environmental Science & Technology. 48 (4): 2097–2098. Bibcode:2014EnST...48.2097S. doi:10.1021/es5002105. ISSN 0013-936X. PMID 24476540. Schymanski, Emma L.; Singer, Heinz P.; Slobodnik, Jaroslav; Ipolyi, Ildiko M.; Oswald, Peter; Krauss, Martin; Schulze, Tobias; Haglund, Peter; Letzel, Thomas; Grosse, Sylvia; Thomaidis, Nikolaos S. (1 August 2015). "Non-target screening with high-resolution mass spectrometry: critical review using a collaborative trial on water analysis". Analytical and Bioanalytical Chemistry. 407 (21): 6237–6255. doi:10.1007/s00216-015-8681-7. hdl:10234/147867. ISSN 1618-2650. PMID 25976391. S2CID 29696368.
Graphene is chemically dormant, mechanically sturdy, and non-permeable to gas or liquid. So, carbon plays a major role for fabrication of nanomaterials with porous nature. Graphene membranes that are formed by graphene oxide molecules or chemically converted graphene that is adhered with 2D nano mediated arrays have the ability to efficiently separate molecules in a gas or in a liquid phase. Graphene-coated nanomembranes are said to be more applicable in water treatment due to its unique properties. Graphene membranes are obtained from vacuum filtration or coating of graphene oxide solution as Graphene oxide sheets. The graphene coated nanofiltration membrane showed a higher water flux range. The graphene embedded with carbon nanotubes to serve as nanofilters is more useful for dye rejection in water effluent, removal of salt ions, and also acts as antifouling agent. Graphene nanofilter membranes possess effective antifouling agent due to its strong bond between graphene sheets and proteins. Also, graphene oxide coated nanofilter membranes helps in dechlorination of water. In addition to this, ultrathin nanofilter coated with graphene is the most potent filter that could be commercialized for water purification. Graphene oxide membranes can be used in various forms such as free, surface modified, and graphene cast in membranes in the range of micro, nano, or ultrafilters. Among which nanofilters is more efficient for water desalination due to its mechanical strength and physiochemical properties of the membrane.
On the day of discovery, 19 February, alpha irradiation of the einsteinium target occurred in three three-hour sessions. The cyclotron was in the University of California campus, while the Radiation Laboratory was on the next hill. To deal with this situation, a complex procedure was used: Ghiorso took the catcher foils (there were three targets and three foils) from the cyclotron to Harvey, who would use aqua regia to dissolve it and pass it through an anion-exchange resin column to separate the transuranium elements from the gold and other products. The resultant drops entered a test tube, which Choppin and Ghiorso took in a car to get to the Radiation Laboratory as soon as possible. Thompson and Choppin used a cation-exchange resin column and the α-hydroxyisobutyric acid. The solution drops were collected on platinum disks and dried under heat lamps. The three disks were expected to contain, respectively, the fermium, no new elements, and the mendelevium. Finally, they were placed in their own counters, which were connected to recorders such that spontaneous fission events would be recorded as huge deflections in a graph showing the number and time of the decays. There thus was no direct detection, but by observation of spontaneous fission events arising from its electron-capture daughter 256Fm. The first one was identified with a "hooray" followed by a "double hooray" and a "triple hooray". The fourth one eventually officially proved the chemical identification of the 101st element, mendelevium. In total, five decays were reported up until 4 a.m.
Sources: en.wikipedia.org
For Charitable Service. Colonel (Rtd) Brian Mark Gorski, MBE. For services to Museums and to the community in Bury, Greater Manchester. Solange Anna-Natasha Urdang. Chief Executive Officer and Founder, The Dang Studios, London, Co-Founder and Director, Black British Theatre Awards and lately Chief Executive Officer, Urdang Academy. For services to Dance and Musical Theatre. Andrew Graham. Deputy Director, Strategic Finance Directorate, Department for Education. For Public Service and to the community in County Durham. Natasha Jane Grant. Deputy Director, Cabinet Office. For Public Service. Edward James Gray. Lately Chair, Antivirals Taskforce. For services to Public Health during Covid-19. Betsy Gregory. For services to Dance. Yvette Mona Griffith. Co-Chief Executive, Jazz re:freshed, Founder Member, GiveBLACK and Founding Trustee, Black Funding Network. For services to Cultural Philanthropy and to Music. Neil Francis Guckian. Chief Executive, The Western Health and Social Care Trust. For services to Health and Social Care and to the community in Northern Ireland. Professor Gavin Halbert. Director, Cancer Research UK Formulation Unit, University of Strathclyde. For services to Cancer Treatment and Research. Professor David Rodney Heath-Brown. Emeritus Fellow, University of Oxford. For services to Mathematics and Mathematical Research. Paul Michael Heygate. Joint Managing Director, Heygate Group. For services to the Food Industry and to Charity. Gordon Arthur Woolnough Hickman. Head of Exotic Disease Policy, Department for Environment, Food and Rural Affairs.
In the US, newborn screening (NBS) is mandated in all states, though in some states parents may decline it for religious or philosophical reasons. Few parents opt for the program due to health concerns, and a lack of awareness of the ability to opt out. After the initial testing is complete, the residual dried blood spots (DBS) on newborn screening cards may be used for secondary purposes, including being shared with law enforcement and sold for research. The decreasing costs of whole genome sequencing have also raised concerns that blood spots may be sequenced in the future, limiting any de-identification procedures. While CLIA does specify minimum retention requirements, it does not specify a federal maximum retention period. Retention periods for NBS cards vary by state; for example, New Jersey stores them for 23 years, and Texas may keep them indefinitely. The absence of parental awareness and consent for these activities, and a lack of transparency and federal regulations, has led to significant public concern and apprehension.
== History == Norketamine was synthesized by Calvin Lee Stevens in the early 1960s, as part of his team's work on α-aminoketones at Wayne State University. While most research has historically focused on its precursor, researchers have taken notice of norketamine's putative effects. Beginning in the late 1990s, Danish researchers discovered its role as a NMDA receptor antagonist. Later research uncovered its use as an antinociceptive, or "painkiller." Following the 2019 approval of the ketamine enantiomer esketamine by the European Medicines Agency and FDA for use with treatment-resistant depression, researchers and pharmaceutical companies have sought other effective intermediates and metabolites of racemic ketamine. Much of the research examining the potential role of norketamine as a distinct anti-depressant to its precursor began in the mid-2010s. Rodent models have showcased that norketamine crosses the blood-brain barrier, though considerably less efficiently than ketamine. Accordingly, its antidepressant effects are less potent than enantiomers of ketamine, but appear to be as effective as esketamine in its potency and duration. Unlike esketamine, (S)-norketamine does not appear to significantly impact prepulse inhibition (reduction of the startle reflex) and as such appears to have significantly fewer psychotomimetic effects - which may indicate that it could be a safer alternative to ketamine for use as an antidepressant in humans.
Bicalutamide monotherapy has been found to decrease circulating levels of prostate-specific antigen (PSA), a marker of prostate cancer growth, by 57% at 10 mg/day, 73% at 30 mg/day, 90% at 50 mg/day, 97% at 100 mg/day, and 97% at 150 mg/day, while a 97% reduction in PSA is observed with 50 mg/day bicalutamide as a part of CAB. It has also been reported that bicalutamide monotherapy decreases median circulating levels of PSA at 3 months by 86.7% at 100 mg/day, 91.1% at 150 mg/day, and 93.8% at 200 mg/day (relative to 94–97% for castration). Above a bicalutamide monotherapy dosage of 200 mg/day, up to 600 mg/day, decreases in PSA levels reach a plateau. In a study of very-high-dose bicalutamide monotherapy, decreases in PSA levels after 12 weeks were approximately 93% with 300 mg/day, 96% with 450 mg/day, 96% with 600 mg/day, and 96% with castration. Earlier studies with bicalutamide instead assessed changes in prostatic acid phosphatase (PAP) levels; proportions of patients with decreases of PAP of greater than or equal to 50% were 33% with 10 mg/day, 53% with 30 mg/day, and 83% with 50 mg/day bicalutamide. PSA is a more sensitive and specific prostate cancer tumor marker than PAP and subsequent studies employed PSA. Despite the high medication levels that are achieved, due to their relatively low affinities for the AR, it has been suggested that 5 to 10% of DHT may remain unblocked in the prostate gland with CAB using standard doses of first-generation NSAAs.
Sources: en.wikipedia.org
== Synthesis == Generally, synthesis of the characteristic scaffold of ebselen, the benzoisoselenazolone ring system, can be achieved either through reaction of primary amines (RNH2) with 2-(chloroseleno)benzoyl chloride (Route I), by ortho-lithiation of benzanilides followed by oxidative cyclization (Route II) mediated by cupric bromide (CuBr2), or through the efficient Cu-catalyzed selenation / heterocyclization of o-halobenzamides, a methodology developed by Kumar et al. (Route III).
=== Comparison of AAS === AAS differ in a variety of ways including in their capacities to be metabolized by steroidogenic enzymes such as 5α-reductase, 3-hydroxysteroid dehydrogenases, and aromatase, in whether their potency as AR agonists is potentiated or diminished by 5α-reduction, in their ratios of anabolic/myotrophic to androgenic effect, in their estrogenic, progestogenic, and neurosteroid activities, in their oral activity, and in their capacity to produce hepatotoxicity.
== Journal of Biomolecular Techniques == The ABRF is the publisher of the Journal of Biomolecular Techniques. The journal is peer-reviewed and is published quarterly. The major focus of the journal is to publish scientific reviews and articles related to biomolecular resource facilities. The Research Group published reports include annual surveys. News and events, as well as an article watch focused on techniques used in typical core facility environments are also included. The current Editor-in-Chief is Ron Orlando, University of Georgia.
Sources: en.wikipedia.org
Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.
No. The peptide is synthetic, although it is modelled on a fragment of a naturally occurring hormone. ACTH(4-10) is generated when ACTH is cleaved, but the Pro-Gly-Pro extension is not a known endogenous sequence. It is therefore a designed analogue rather than a natural metabolite.
The label reflects reported effects on attention, memory and recovery after neurological injury in regional clinical reports. Those reports are mostly small and have not been widely replicated outside the region. The classification is descriptive and does not imply a single defined mechanism.
It is registered as a pharmaceutical product in Russia, where it is typically supplied as a nasal solution. In most other countries it is not an approved drug and is traded as a research chemical instead. Approval status depends entirely on the jurisdiction involved.